---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-017141"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:34:20.345003+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant reports positive Phase 2 NIU data; authorizes $1.5B buyback, repurchases Sumitomo's 9% stake

## Summary
- Phase 2 NEPTUNE: brepocitinib 45mg arm had 29% Treatment Failure at week 24 (vs 44% for 15mg), best observed in NIU studies.
- All secondary endpoints positive; 43% of patients with baseline macular edema achieved resolution by week 24 on 45mg.
- Board authorized up to $1.5B share repurchase; $648.4M to buy Sumitomo's 71.3M shares at $9.10, reducing shares outstanding by ~9%.
- Phase 3 program in NIU to start H2 2024; Phase 3 dermatomyositis study fully enrolled Q3 2024, data expected 2025.

## SEC filing metadata
- accession: 0001140361-24-017141
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/0001140361-24-017141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124017141/ef20025692_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-017141
- JSON: https://secwatch.observer/filing/0001140361-24-017141.json
- Plain text: https://secwatch.observer/filing/0001140361-24-017141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.